Bristol-Myers Squibb Company Ties Hepatitis C Success To Rival Gilead Sciences, Inc.'s Pill

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Bristol-Myers Squibb Co. (BMY) will try to grab an early share of the multibillion-dollar market for new hepatitis C treatments by piggybacking its experimental drug with Gilead Sciences Inc. (GILD)’s approved pill.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC